The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation

As a new anticancer treatment option, vaccinia virus (VACV) has shown remarkable antitumor activities (oncolysis) in preclinical studies, but potential infection of other organs remains a safety concern. We present here genome comparisons between the de novo sequence of GLV-1h68, a recombinant VACV,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qian, Liang, Chunguang, Yu, Yong A., Chen, Nanhai, Dandekar, Thomas, Szalay, Aladar A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746888/
https://www.ncbi.nlm.nih.gov/pubmed/19701652
http://dx.doi.org/10.1007/s00438-009-0475-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746888/
https://www.ncbi.nlm.nih.gov/pubmed/19701652
http://dx.doi.org/10.1007/s00438-009-0475-1

Ejemplares similares